Cerro Pacific Wealth Advisors LLC Sells 4,721 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Cerro Pacific Wealth Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 61.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,008 shares of the biopharmaceutical company’s stock after selling 4,721 shares during the quarter. Cerro Pacific Wealth Advisors LLC’s holdings in Gilead Sciences were worth $278,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. nVerses Capital LLC bought a new position in Gilead Sciences during the third quarter worth $25,000. Valued Wealth Advisors LLC grew its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the period. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the 4th quarter worth about $29,000. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Quarry LP bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock worth $42,130,461 over the last three months. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 0.1 %

NASDAQ:GILD opened at $92.92 on Friday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a 50-day moving average price of $91.63 and a two-hundred day moving average price of $84.63. The firm has a market cap of $115.80 billion, a price-to-earnings ratio of 1,032.44, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company posted $2.29 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GILD shares. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.